UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S53-S54

2015

Volltextzugriff (PDF)

324 Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure–adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitor

European journal of cancer (1990), 2014-11, Vol.50, p.105-106

2014

Volltextzugriff (PDF)

364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma

European journal of cancer (1990), 2014-11, Vol.50, p.117-117

2014

Volltextzugriff (PDF)

27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target

ESMO open, 2023-03, Vol.8 (1), p.100993, Article 100993

2023

Volltextzugriff (PDF)

Association of an HLA-DQ allele with clinical tuberculosis

JAMA : the journal of the American Medical Association, 1998-01, Vol.279 (3), p.226

1998

Volltextzugriff (PDF)

Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results

Annals of oncology, 2012-09, Vol.23, p.ix158

2012

Volltextzugriff (PDF)

399 Pharmacokinetics and Pharmacodynamics of TAK-733, an Investigational, Oral MEK Inhibitor, in Patients with Advanced Nonhematologic Malignancies

European journal of cancer (1990), 2012-11, Vol.48, p.121-122

2012

Volltextzugriff (PDF)

162 Drug–drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data

European journal of cancer (1990), 2014-11, Vol.50, p.54-55

2014

Volltextzugriff (PDF)

1096 The PARP14 inhibitor RBN-3143 suppresses skin inflammation in preclinical models

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S188-S188

2023

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of fluorescent ligands for MT 1 and/or MT 2 melatonin receptors

RSC advances, 2016, Vol.6 (67), p.62508-62521

2016

Volltextzugriff (PDF)

Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

Cancer, 2006-06, Vol.106 (11), p.2437-2444

2006

Volltextzugriff (PDF)

Reconstitution of a High-Affinity Functional Lutropin Receptor by Coexpression of Its Extracellular and Membrane Domains

Biochemical and biophysical research communications, 1993-06, Vol.193 (3), p.1023-1030

1993

Volltextzugriff (PDF)

Peptide and immunochemical mapping of the ectodomain of the porcine LH receptor

Journal of molecular endocrinology, 1996-02, Vol.16 (1), p.15-25

1996

Volltextzugriff (PDF)

Error rate for HLA-B antigen assignment by serology: implications for proficiency testing and utilization of DNA-based typing methods

Tissue antigens, 1997-10, Vol.50 (4), p.387-394

1997

Volltextzugriff (PDF)

Endocytosis of lutropin by Leydig cells through a pathway distinct from the high-affinity receptor

Molecular and cellular endocrinology, 1998-08, Vol.143 (1), p.33-42

1998

Volltextzugriff (PDF)

Influence of promoter and signal peptide on the expression and secretion of recombinant porcine LH extracellular domain in baculovirus/lepidopteran cells or the caterpillar system

Journal of molecular endocrinology, 1995-06, Vol.14 (3), p.277-284

1995

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of fluorescent ligands for MT1 and/or MT2 melatonin receptorsElectronic supplementary information (ESI) available. See DOI: 10.1039/c6ra10812a

2016-06

Volltextzugriff (PDF)

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS145-TPS145

2011

Volltextzugriff (PDF)

High-level expression of recombinant porcine LH receptor in baculovirus-infected insect cells or caterpillars

Journal of molecular endocrinology, 1995-02, Vol.14 (1), p.51-66

1995

Volltextzugriff (PDF)

Agonist-like activity of antibodies directed against the second extracellular loop of the human cardiac serotonin 5-HT4(e) receptor in transfected COS-7 cells

Receptors & channels, 2002, Vol.8 (2), p.113-121

2002

Volltextzugriff (PDF)

Agonist like effects of an antipeptidic antibody (AC G21V) raised against the exoloop 2 on human cardiac recombinant 5-HT4 receptor activity

Biochemical Society transactions, 2000-10, Vol.28 (5), p.A254-A254

2000

Volltextzugriff (PDF)

Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.8036-8036

2006

Volltextzugriff (PDF)

Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.8032-8032

2006

Volltextzugriff (PDF)

Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.8033-8033

2006

Volltextzugriff (PDF)

Cardiac 5_HT4 receptor in children: functional and pharmacological characteristics

Journal of molecular and cellular cardiology, 2006-06, Vol.40 (6), p.991-991

2006

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma

324 Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure–adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitor

364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma

27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target

Association of an HLA-DQ allele with clinical tuberculosis

Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results

399 Pharmacokinetics and Pharmacodynamics of TAK-733, an Investigational, Oral MEK Inhibitor, in Patients with Advanced Nonhematologic Malignancies

162 Drug–drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical data

1096 The PARP14 inhibitor RBN-3143 suppresses skin inflammation in preclinical models

Design, synthesis and biological evaluation of fluorescent ligands for MT 1 and/or MT 2 melatonin receptors

Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

Reconstitution of a High-Affinity Functional Lutropin Receptor by Coexpression of Its Extracellular and Membrane Domains

Peptide and immunochemical mapping of the ectodomain of the porcine LH receptor

Error rate for HLA-B antigen assignment by serology: implications for proficiency testing and utilization of DNA-based typing methods

Endocytosis of lutropin by Leydig cells through a pathway distinct from the high-affinity receptor

Influence of promoter and signal peptide on the expression and secretion of recombinant porcine LH extracellular domain in baculovirus/lepidopteran cells or the caterpillar system

Design, synthesis and biological evaluation of fluorescent ligands for MT1 and/or MT2 melatonin receptorsElectronic supplementary information (ESI) available. See DOI: 10.1039/c6ra10812a

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma

High-level expression of recombinant porcine LH receptor in baculovirus-infected insect cells or caterpillars

Agonist-like activity of antibodies directed against the second extracellular loop of the human cardiac serotonin 5-HT4(e) receptor in transfected COS-7 cells

Agonist like effects of an antipeptidic antibody (AC G21V) raised against the exoloop 2 on human cardiac recombinant 5-HT4 receptor activity

Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival

Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma

Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab

Cardiac 5_HT4 receptor in children: functional and pharmacological characteristics

Suchergebnisse filtern